AB-PINACA：修订间差异
删除的内容 添加的内容
←建立内容为“{{Drugbox | IUPAC_name = ''N''-[(1''S'')-1-(Aminocarbonyl)-2-methylpropyl]-1-pentyl-1''H''-indazole-3-carboxamide | image = AB-PINACA_structure-rev1.png <!--Clinical data--> | tradename = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category = | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | legal_CA = Schedule II | legal_UK = Class B | legal…”的新页面 |
（没有差异）
|
2023年1月26日 (四) 10:27的版本
 | |
| 法律規範狀態 | |
|---|---|
| 法律規範 |
|
| 识别信息 | |
| |
| CAS号 | 1445752-09-9  |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| 化学信息 | |
| 化学式 | C18H26N4O2 |
| 摩尔质量 | 330.43 g·mol−1 |
| 3D模型（JSmol） | |
| |
| |
AB-PINACA是一种有机化合物，化学式为C18H26N4O2。它最初由辉瑞公司于2009年作为镇痛药开发，[1][2]并在2012年于日本首次被鉴定为{{le|合成大麻素|synthetic cannabinoids]]。[3]
它是潜在的CB1受体（Ki = 2.87 nM，EC50 = 1.2 nM）和CB2受体（Ki = 0.88 nM，EC50 = 2.5 nM）的激动剂。[4][5]
这种合成大麻素有不少相关死亡和住院病例报告。[6]
参见
参考文献
- ^ AB-PINACA. Cayman Chemical. [25 June 2015].
- ^ Patent WO/2009/106980 - Indazole derivatives.
- ^ Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y. New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicology. 2012, 31: 93–100. S2CID 25242453. doi:10.1007/s11419-012-0171-4.
- ^ Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, et al. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience. September 2015, 6 (9): 1546–59. PMID 26134475. doi:10.1021/acschemneuro.5b00112.
- ^ Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, et al. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice. The Journal of Pharmacology and Experimental Therapeutics. September 2015, 354 (3): 328–39. PMC 4538877
. PMID 26105953. doi:10.1124/jpet.115.225326.
- ^ Trecki J, Gerona RR, Schwartz MD. Synthetic Cannabinoid-Related Illnesses and Deaths. The New England Journal of Medicine. July 2015, 373 (2): 103–7. PMID 26154784. doi:10.1056/NEJMp1505328.
